Oxford Cannabinoid Technologies Holdings, one of the UK’s few remaining pharmaceutical cannabis companies, appears to have entered administration.
Earlier this week, Jazz dismissed a patent claim against Apotex, Canada’s largest generic drug producer, as it reached a settlement with the company, the details of which were undisclosed.
Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful completion of ‘proof of concept’ of its
A cannabinoid drug company has opted to undertake its trials in America due to the complexities of the UK’s licensing regime.
Chill Brands [stock_market_widget type=”chart” template=”line” assets=”CHLL.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] The CBD and
Last week, UK biotechnology firm Oxford Cannabinoid Technologies (OCT), one of the first cannabis companies in history to list on
Synbiotic [stock_market_widget type=”chart” template=”line” assets=”SBX.DE” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] German cannabis group SynBiotic
Oxford Cannabinoid Technologies [stock_market_widget type=”chart” template=”line” assets=”OCTP.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Oxford Cannabinoid
MGC Pharmaceuticals / Argent BioPharma [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”MXC.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] MGC Pharmaceuticals
Cellular Goods (Cel AI) [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”CBX.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Cellular Goods has
Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, is pleased to announce that dosing of
This week, British pharmaceutical cannabis firm Oxford Cannabinoid Technologies (OCT) announced that the ‘final dose’ in its crucial Phase I
The UK’s National Health Service (NHS) Research Ethics Committee this week approved the full-scale rollout of a new clinical trial
Oxford Cannabinoid Technologies [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”OCTP.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Oxford Cannabinoid Technologies announced
OCTP, the pharmaceutical company developing prescription cannabinoid medicines, is formally expanding its research and development strategy into oncology having identified
Oxford Cannabinoid Technologies [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”OCTP.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] The London Stock
We won’t spam you
